Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage IVC Colorectal Cancer, Colorectal Cancer Metastatic
Interventions
Metformin, Nivolumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation
Interventions
Tovorafenib, Tovorafenib Drug: Pimasertib
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more
Conditions
Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer, Bladder Cancer, Sarcoma, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Squamous Cell Carcinoma
Interventions
PF-07263689, Sasanlimab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Duarte, California • New York, New York
Conditions
Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer, Renal Cell Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
6
States / cities
New Haven, Connecticut • Boston, Massachusetts • Buffalo, New York + 3 more
Conditions
Breast Cancer, Cervical Cancer, Colon Cancer, Rectal Cancer, Abnormal Breast Cancer Screening Tests, Abnormal Cervical Cancer Screening Tests, Abnormal Colon Cancer Screening Tests
Interventions
Patient Navigator matched with subject, Subjects are mailed informational/educational materials
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer
Interventions
Niraparib
Drug
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
80
States / cities
Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more
Completed Phase 1 Interventional Results available

Safety Study of PLX4032 in Patients With Solid Tumors

NCT00405587
Conditions
Malignant Melanoma, Colorectal Carcinoma
Interventions
PLX4032
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
5
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 2 more
Conditions
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
Interventions
PF-08052666
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Fairway, Kansas • Kansas City, Kansas + 6 more
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
irinotecan hydrochloride, adjuvant therapy, conventional surgery, radiofrequency ablation
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Cleveland, Ohio • Seattle, Washington
Conditions
Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage II Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8, Stage IIIA Anal Cancer AJCC v8, Stage IIIB Anal Cancer AJCC v8, Stage IIIC Anal Cancer AJCC v8
Interventions
Cisplatin, Fluorouracil, Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Radiation · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Neoplasms, Ovarian Neoplasms, Colonic Neoplasms, Prostatic Neoplasms, Uterine Cervical Neoplasms, Leukemia, Lymphoma, Non-Hodgkin
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
992 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Colorectal Neoplasia
Interventions
Omeprazole, Aspirin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Conditions
Colorectal Cancer
Interventions
Capecitabine, Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
48
States / cities
Mobile, Alabama • Alhambra, California • Bakersfield, California + 43 more
Conditions
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
177Lu-BetaBart
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska
Conditions
Colorectal Cancer, Pancreatic Ductal Cancer, Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
Interventions
BGB-3245, Panitumumab
Drug
Lead sponsor
MapKure, LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Duarte, California • Durham, North Carolina • Fairfax, Virginia
Conditions
Rectal Neoplasms
Interventions
fludeoxyglucose F 18, positron emission tomography, magnetic resonance imaging, laboratory biomarker analysis
Radiation · Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Colorectal Cancer Metastatic
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Scottsdale, Arizona • New Orleans, Louisiana • Las Vegas, Nevada + 3 more
Conditions
Colon Cancer
Interventions
BLI850, polyethylene glycol 3350 based bowel preparation
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
12
States / cities
Mobile, Alabama • Jupiter, Florida • Miami, Florida + 9 more
Conditions
Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
Interventions
Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2)
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Refractory Metastatic Colorectal Cancer
Interventions
TAS-102, nivolumab
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
Conditions
Colorectal Cancer
Interventions
SBIRT, Referral as Usual (RAU)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
45 Years and older
Enrollment
880 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Completed Phase 1Phase 2 Interventional Results available

Lidocaine for Oxaliplatin-induced Neuropathy

NCT03254394
Conditions
Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer
Interventions
Lidocaine Hydrochloride, Placebo, FOLFOX regimen
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
Interventions
LY3410738, Gemcitabine, Cisplatin, Durvalumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
Conditions
Colorectal Cancer
Interventions
cetuximab, Irinotecan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
116
States / cities
Tucson, Arizona • Pine Bluff, Arkansas • Bakersfield, California + 104 more